Patents by Inventor Patricia A. Culp
Patricia A. Culp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11976119Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPA polypeptide, e.g., a mammalian SIRPA or human SIRPA, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: March 29, 2022Date of Patent: May 7, 2024Inventors: Andrew Pincetic, Wei-Hsien Ho, Patricia Culp, Arnon Rosenthal
-
Patent number: 11965023Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-5 protein, e.g., human Siglec-5 or a mammalian Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: May 9, 2022Date of Patent: April 23, 2024Assignee: Alector LLCInventors: Kate Monroe, Helen Lam, Patricia Culp, Arnon Rosenthal
-
Publication number: 20240026011Abstract: The invention relates to Conditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind one or more tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment. In some embodiments, the tumor target antigen includes B7H3, CA9 (CAIX), EGFR, EpCAM, FOLR1, HER2, LyPD3, and/or Trop2.Type: ApplicationFiled: August 17, 2021Publication date: January 25, 2024Applicant: Takeda Pharmaceutical Company LimitedInventors: Robert B. DuBridge, Tseng-hui Timothy Chen, Patricia Culp, Chad Michael May, Danielle Dettling, Jeremiah Degenhardt
-
Publication number: 20230340159Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind one or more tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment. In some embodiments, the tumor target antigen includes B7H3, CA9 (CAIX), EGFR, EpCAM, FOLR1, HER2, LyPD3, and/or Trop2.Type: ApplicationFiled: February 22, 2023Publication date: October 26, 2023Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Robert B. DuBridge, Tseng-hui Timothy Chen, Patricia A. Culp, Chad Michael May, Danielle Dettling, Jeremiah Daniel Degenhardt
-
Publication number: 20230312715Abstract: Provided herein are Conditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format, which includes a human semm albumin (HSA) domain that increases its semm half-life. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, and thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.Type: ApplicationFiled: September 3, 2021Publication date: October 5, 2023Applicant: Takeda Pharmaceutical Company LimitedInventors: Robert B. DuBridge, Daniel J. Hicklin, Patricia A. Culp
-
Publication number: 20220315656Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-5 protein, e.g., human Siglec-5 or a mammalian Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: May 9, 2022Publication date: October 6, 2022Applicant: Alector LLCInventors: Kate MONROE, Helen LAM, Patricia CULP, Arnon ROSENTHAL
-
Publication number: 20220289844Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPA polypeptide, e.g., a mammalian SIRPA or human SIRPA, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: March 29, 2022Publication date: September 15, 2022Applicant: Alector LLCInventors: Andrew Pincetic, Wei-Hsien Ho, Patricia Culp, Arnon Rosenthal
-
Patent number: 11359014Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-5 protein, e.g., human Siglec-5 or a mammalian Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: May 15, 2018Date of Patent: June 14, 2022Assignee: Alector LLCInventors: Kate Monroe, Helen Lam, Patricia Culp, Arnon Rosenthal
-
Publication number: 20220162309Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: January 21, 2022Publication date: May 26, 2022Applicant: ALECTOR LLCInventors: Patricia CULP, Helen LAM, Arnon ROSENTHAL, Seung-Joo LEE, Nels P. NIELSON, Robert PEJCHAL
-
Patent number: 11319373Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPA polypeptide, e.g., a mammalian SIRPA or human SIRPA, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: May 24, 2019Date of Patent: May 3, 2022Assignee: Alector LLCInventors: Andrew Pincetic, Wei-Hsien Ho, Patricia Culp, Arnon Rosenthal
-
Patent number: 11254743Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: May 7, 2020Date of Patent: February 22, 2022Assignee: ALECTOR LLCInventors: Patricia Culp, Helen Lam, Arnon Rosenthal, Seung-Joo Lee, Nels P. Nielson, Robert Pejchal
-
Publication number: 20210395361Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a Siglec-5 protein, e.g., human Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: July 26, 2019Publication date: December 23, 2021Applicant: Alector LLCInventors: Patricia CULP, Rashmi BANKOTI, Helen LAM, Arnon ROSENTHAL
-
Publication number: 20210317208Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a CD33 polypeptide, e.g., a mammalian CD33 or human CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: August 30, 2019Publication date: October 14, 2021Applicant: Alector LLCInventors: Patricia CULP, Helen LAM, Wei-Hsien HO, Leonard G. PRESTA, Arnon ROSENTHAL
-
Publication number: 20210277113Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRP?1 polypeptide, e.g., a human SIRP?1, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: June 28, 2019Publication date: September 9, 2021Applicant: Alector LLCInventors: Andrew Pincetic, Patricia Culp, Arnon Rosenthal
-
Publication number: 20210246204Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: June 7, 2019Publication date: August 12, 2021Applicant: Alector LLCInventors: Patricia CULP, Seung-Joo LEE, Helen LAM, Wei-Hsien HO, Arnon ROSENTHAL
-
Publication number: 20210139581Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: May 7, 2020Publication date: May 13, 2021Applicant: ALECTOR LLCInventors: Patricia CULP, Helen LAM, Arnon ROSENTHAL, Seung-Joo LEE, Nels P. NIELSON, Robert PEJCHAL
-
Publication number: 20210017275Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-5 protein, e.g., human Siglec-5 or a mammalian Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: May 15, 2018Publication date: January 21, 2021Applicant: Alector LLCInventors: Kate MONROE, Helen LAM, Patricia CULP, Arnon ROSENTHAL
-
Patent number: 10711062Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: August 3, 2018Date of Patent: July 14, 2020Assignee: ALECTOR LLCInventors: Patricia Culp, Helen Lam, Arnon Rosenthal, Seung-Joo Lee, Nels P. Nielson, Robert Pejchal
-
Publication number: 20190359707Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPA polypeptide, e.g., a mammalian SIRPA or human SIRPA, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: May 24, 2019Publication date: November 28, 2019Applicant: Alector LLCInventors: Andrew Pincetic, Wei-Hsien Ho, Patricia Culp, Arnon Rosenthal
-
Patent number: 10233258Abstract: The present disclosure provides bispecific proteins that bind to two antigens, as well as their compositions, uses, and methods of making.Type: GrantFiled: February 23, 2018Date of Patent: March 19, 2019Assignee: AbbVie Biotherapeutics Inc.Inventors: Yoshiko Akamatsu, Patricia Culp, Charles M. Forsyth, Ping Y. Huang, David Powers, Alan F. Wahl, Shiming Ye
